Introduction
In multiple myeloma (MM) as in virtually all hematologic malignancies there is a correlation between depth of response and prolonged survival. 1 Over the past 20
years, significantly higher rates of complete response (CR) have been achieved contributing to improve MM patients' outcome. 2 However, long-term follow-up studies have shown that approximately two thirds of these will not sustain their CR, and relapse before they can be considered as achieving "operational cure" (i.e.: more than 10-years progression-free survival). 3 Relapses among MM patients in CR are now better understood and predicted with the advent of minimal residual disease (MRD) studies, which have shown an intrinsic correlation between the persistence of reduced numbers of clonal plasma cells (PCs) after therapy (i.e.: MRD) and inferior survival. [4] [5] [6] [7] Thus, MRD represents a very small fraction of all diagnostic tumor cells which are chemoresistant, potentially quiescent (not producing M-protein), and able to recapitulate the initial tumor burden at relapse.
Overall, there are two putative mechanisms by which chemoresistance may arise in cancer; i) therapy-induced molecular alterations, and ii) presence of cellular heterogeneity within the tumor bulk where several subclones coexist and compete with each other in such a way that treatment eradicates the major subclone (chemosensitive), but a minor, resistant and initially dormant subclone subsequently expands and gives rise to disease relapse. 8 In MM, the first mechanism has been suggested to explain chemoresistance to proteasome inhibition (e.g.: acquired mutations in genes encoding proteasome beta subunits 9 or decreased endoplasmic reticulum -ER-stress signaling 10 ) and immunomodulatory agents (e.g.: decreased cereblon expression 11, 12 , over-expression hyaluronan binding proteins such as CD44 13 ), or upregulation of the MEK/ERK pathway. 14 In turn, the second mechanism would explain the shift in dominance of tumor subclones over time in paired samples from MM patients studied at diagnosis vs. relapse. [15] [16] [17] Of note, chemoresistance may also result from the combination of both mechanisms; for example, when less differentiated myeloma PC clones down-regulate specific transcriptional factors to overcome treatment (e.g.: suppression of Xbp1s to diminish ER front-loading and cytotoxic susceptibility to proteasome inhibition). 18 Despite all the above, both hypothetical mechanisms rely on data generated from the study of clonal PCs at the time of relapse, while no biologic studies have been performed in primary chemoresistant clonal PCs that persist at MRD levels after frontline therapy before the patients' relapse.
MRD monitoring has become one of the most relevant prognostic factors in MM, independently of patients' serological response and diagnostic cytogenetic profile. 5 Thus, it has been shown that the outcome of patients with standard-or high-risk cytogenetics is modulated by the persistence vs. eradication of MRD 5 but also that, particularly among MRD-positive cases, survival is significantly inferior in patients with clonal PCs harboring high-risk cytogenetic abnormalities. 5 Group criteria 19 were prospectively studied after inclusion in the GEM2010MAS65 trial (NCT01237249). In all patients, bone marrow (BM) aspirates were collected at diagnosis and after nine cycles of induction therapy. In brief, patients treatment consisted of either nine identical induction cycles with bortezomib, melphalan, prednisone (VMP; n=21), or alternating cycles of VMP and lenalidomide plus low-dose dexamethasone (Rd) for up to nine courses (n=19). Samples were collected after 
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; ii) CD11c, CD45, CD41a, CD49e, CD33, CD117, CD19, CD38; iii) CD20, CD45, CD81, CD54, CD138, CD56, CD19, CD38, and; iv) HLA-DR, CD45, CD44, CXCR4, CD27, CD28, CD19, CD38. Markers were selected based on their role to identify the PC compartment (CD38, CD138), discriminate clonal from normal PCs within the PC compartment (CD19, CD20, CD27, CD28, CD45, CD56, CD81, CD117), define Bcell/PC differentiation (CD19, CD20, CD27, CD45, CD79b, CD81, HLADR), to mediate cell-to-cell interactions (CD28, CD117), and in cell-adhesion-mediated-drug-resistance (CAM-DR: CD11a, CD11c, CD29, CD41a, CD44, CD49d, CD49e, CD54, CXCR4, β7).
Data acquisition was performed for approximately 10 6 leukocytes/tube in a FACSCantoII flow cytometer (Becton Dickinson Biosciences -BDB -San Jose, CA) using the FACSDiva 6.1 software (BDB). Instrument performance was daily monitored using the Cytometer Setup Tracking (CST; BDB) and rainbow 8-peak beads (Spherotech, Inc; Lake Forest, IL) after laser stabilization, following the EuroFlow guidelines 20 ; sample acquisition was performed only in case of longitudinal instrument stability. In Supplementary Figure 1 , the expression levels of CD19 in mature B-cells from BM samples assessed at diagnosis and after induction are represented, and confirm the longitudinal instrument stability. Per protocol, newly-diagnosed MM patients included in the GEM2010MAS65 trial had BM samples studied after 9 induction cycles to monitor MRD levels; whenever persistent clonal PCs were detected (MRD-positive), exactly the same immunophenotypic method performed at diagnosis was repeated for the characterization of the chemoresistant clone after therapy. MoAb combination (aliquot), this included data about those antigens that were measured directly on it and antigens which were not evaluated directly ("missing values") for that cell in the corresponding aliquot it was contained in. Then, the calculation function of the Infinicyt software was used to fill in the "missing values", based on the "nearest neighbor" statistical principle 23, 24 , defined by the unique position , and comparing merged patient-paired iPEP of baseline (diagnostic) vs.
Generation of immunophenotypic protein expression profiles (iPEP

MRD myeloma PCs.
Copy number and gene expression profiling of baseline vs. MRD patient-paired myeloma PCs. Per-protocol, clonal PCs from diagnostic samples were isolated from BM aspirates using CD138 + immunomagnetic beads (Miltenyi Biotech, Bisley, UK).
Following induction therapy, BM aspirates were obtained to determine patients' MRD response at cycle 9, and clonal PCs from MRD-positive cases were FACS-sorted (FACSAria II, BDB; purity ≥97%) according to patient-specific aberrant phenotypes.
DNA from matched diagnostic and MRD clonal PCs was available in 8/40 patients, as well as in 4 additional cases treated with six induction cycles with VRD, making a total of 12 patients. Afterwards, genome-wide detection of copy-number abnormalities (CNAs) and loss of heterozygosity (LOH) were investigated using the standard Affymetrix Cytoscan 750K platform (Affymetrix, Santa Clara, CA, USA). An unpaired analysis was performed using 240 Hapmap files as reference for normal DNA. The complete data set was analyzed by visual inspection using the AGCC and ChAS software programs (Affymetrix). CNAs were reported when the three following criteria were met: ≥25 consecutive imbalanced markers per segment; ≥100Kb minimum genomic size and; <50% overlap with paired control DNA and/or genomic variants of Toronto DB (DGV). 27 Only copy number-neutral loss of heterozygosity (CNN-LOH)
larger that 5Mb were considered.
Gene expression profiling (GEP) was performed in matched diagnostic and MRD clonal PCs from 7/40 cases with adequate RNA extracted from CD138+ and patient-specific phenotypically aberrant FACS-purified tumor cells, respectively. Briefly, the integrity of the extracted RNA was assessed using the Agilent 2100 Bioanalyzer.
Afterward, RNA was amplified, labeled, and subsequently hybridized to the Human Gene 1.0 ST Array (Affymetrix). 28 Normalization was carried out by using the expression console (Affymetrix) with the RMA algorithm which includes background correction, normalization and calculation of expression values (log2). 29 The SIMFIT (http://www.simfit.org.uk/) statistical software was used to perform hierarchical clustering analyses based on Euclidean distances and the group average linkage method. Differentially expressed genes between classes were identified using the Significant Analysis of Microarrays (SAM) algorithm (http://www-stat.standford.edu/-tibs/SAM), and significant genes were selected based on the lowest q-value (<0.05). 28, 29 We used the WebGestalt online suite 30 Figure 4) .
Discussion
Understanding MM genomic and molecular heterogeneity is required to develop treatment strategies that could target dominant but also subclonal reservoirs of chemoresistant cells. While clonal heterogeneity at diagnosis and clonal tiding from diagnosis to patients' relapse has been recently described [15] [16] [17] 21, 33 , no attention has been paid to primary chemoresistant PCs that persist even among patients in serological response (i.e.: MRD). In particular, it has been suggested that mature CD138 + PCs give rise to more immature CD138 lo pre-PCs/plasmablasts that secrete lower immunoglobulin levels (and are thereby less susceptible to ER stress) 18 and could be specifically involved in disease dissemination. 37 [40] [41] [42] [43] [44] [45] , as well as to patients' survival [46] [47] [48] , which would be potentially due to a stronger attachment of MRD clonal PCs to the BM stroma, which provides higher protection from chemotherapyinduced apoptosis. 49, 50 In fact, it could be hypothesized that a subset of chemoresistant MRD cells strongly attached to the stroma might be potentially underestimated in BM aspirates. By contrast, a different role has been assigned to CD44 in cell-adhesion mediated drug resistance (CAM-DR) in several cancers including MM, where CD44 may partially contribute to dexamethasone resistance 51 and becomes upregulated in lenalidomide-resistant MM cells to stabilize the expression of P-glycoprotein, a multidrug resistance efflux pump responsible for the cellular uptake of lenalidomide. 13, 52 Interestingly, differences between diagnostic vs. MRD cells were more pronounced among patients treated only with VMP vs. cases exposed to VMP and Rd. Altogether, However, it is unlikely that all the differences observed were acquired upon treatment exposure; instead, it is most likely that a significant number of such CNAs are present at subclonal levels, but because the methodology used in the present study can only detect abnormalities that are present in 20% or more of clonal PCs cells 17 , they may have gone undetected (Supplementary Figures 6 and 7) . Altogether, these findings are of high relevance since they illustrate that small subclones carrying unique cytogenetic abnormalities may become the predominant population after chemotherapy, and according to the specific type of genetic alteration acquired or lost, influence patients' One potential caveat of the present study is the sole focus on clonal and mature PCs, since the MRD compartment may also reside among CD138 -cells that are expected to have lower expression of ER-genes. 18 However, our experience on the comparison of MRD levels determined by MFC (that focus on the CD138 + PC compartment) vs. molecular methods (that measure clonotypic VDJ rearrangements in whole BM samples), shows a highly significant correlation between the number of MRD cells detected by both techniques. 4, 6 Accordingly, if CD138 -MRD "stem cells" exist, they would be present at levels <10 -6 and therefore, virtually impossible to identify and study using current technology. 
